Trials / Completed
CompletedNCT05607979
Restoring Tissue and Evaluating Novel Treatments for Efficacy in Wounds
The RENEW Study: (Restoring Tissue and Evaluating Novel Treatments for Efficacy in Wounds): A Non-Inferiority Study
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 75 (actual)
- Sponsor
- Lavior Pharma Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an IRB-approved multicenter study.This non-inferiority study aims to evaluate differential healing rates between Lavior Diabetic Wound Gel and other Hydrogels. Study therapy will be started in the outpatient setting and followed accordingly.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lavior Diabetic Wound Gel | Daily application of hydrogel treatment for 60 days. |
| DRUG | Smith & Nephew Solosite Gel Hydrogel Wound Dressing | Daily application of hydrogel treatment for 60 days. |
Timeline
- Start date
- 2022-12-15
- Primary completion
- 2024-05-01
- Completion
- 2024-05-01
- First posted
- 2022-11-07
- Last updated
- 2024-10-08
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05607979. Inclusion in this directory is not an endorsement.